Patent
Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
| العنوان: | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
|---|---|
| Patent Number: | 9,387,176 |
| تاريخ النشر: | July 12, 2016 |
| Appl. No: | 12/598279 |
| Application Filed: | April 30, 2008 |
| مستخلص: | The present invention relates to a method for spray-drying of protein solutions and the spray-dried protein product. The invention also relates to pharmaceutical compositions containing such spray-dried protein, to methods of treating diabetes and hyperglycaemia using the spray-dried protein of the invention and to the use of such spray-dried protein in the treatment of diabetes and hyperglycaemia. |
| Inventors: | Havelund, Svend (Bagsværd, DK); Jensen, Simon Bjerregaard (Hillerød, DK) |
| Assignees: | Novo Nordisk A/S (Bagsvaerd, DK) |
| Claim: | 1. A process for drying a protein solution to obtain a dried protein with a specified pH, the process comprising: a) selecting a target pH for the dried protein, wherein the target pH for the dried protein is between 6.0 and 8.5, b) selecting a target pH for the protein solution wherein the target pH for the protein solution is at least about 0.5 pH units above the target pH for the dried protein selected in step (a), and wherein the target pH for the protein solution is between 7.4 and 11.0, c) obtaining the protein solution at a temperature below 8° C. by steps (i)-(v), wherein the steps (ii)-(v) can be carried out in any order while stirring continuously, i. providing an aqueous phase, ii. adding a protein, iii. optionally adding excipients, iv. adjusting the pH with a non-volatile base and optionally a non-volatile acid to the target pH for the dried protein selected in step (a), v. adjusting the pH with a volatile base to the target pH for the protein solution selected in step (b), and d) drying the protein solution resulting from step (c) to obtain a dried protein with a pH selected in step (a), and wherein the protein is selected from the group consisting of insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, glucagon and/or any combination thereof. |
| Claim: | 2. The process according to claim 1 , wherein step (v) comprises adjusting the pH of the protein solution by at least 0.5 pH unit with the volatile base. |
| Claim: | 3. The process according to claim 1 , comprising in step (iii) adding an excipient selected from a buffer, a detergent, a stabilizer, a protease inhibitor, a flavour, a carrier, an absorption protracting agent, a bulking agent, an agent improving the flowing properties, a penetration enhancer, or a combination hereof. |
| Claim: | 4. The process according to claim 1 , comprising in step (iii) adding glycylglycine and/or phenol. |
| Claim: | 5. The process according to claim 4 , comprising in step (iii) adding about 4 moles of phenol per mole of protein. |
| Claim: | 6. The process according to claim 1 , wherein the drying method is selected from the group consisting of spray drying, spray freeze drying, fluid bed drying, freeze drying and vacuum drying. |
| Claim: | 7. The process according to claim 1 , wherein the target pH of the protein solution in step (b) is at least about 0.7 pH units above the target pH of the dried protein. |
| Claim: | 8. The process according to claim 7 , wherein the target pH of the protein solution in step (b) is at least about 0.9 pH units above the target pH of the dried protein. |
| Patent References Cited: | 2832685 April 1958 Scott 3528960 September 1970 Haas et al. 3719655 March 1973 Jackson 3869437 March 1975 Lindsay et al. 3950517 April 1976 Lindsay et al. 4033941 July 1977 Stilz et al. 4179337 December 1979 Davis et al. 5053389 October 1991 Balschmidt et al. 5179189 January 1993 Domb et al. 5359030 October 1994 Ekwuribe 5478575 December 1995 Miyazaki et al. 5506202 April 1996 Vertesy et al. 5506203 April 1996 Bäckström et al. 5898067 April 1999 Balschmidt et al. 5922675 July 1999 Baker et al. 6221837 April 2001 Ertl et al. 6251856 June 2001 Markussen et al. 6451349 September 2002 Robinson et al. 6500645 December 2002 Kjeldsen et al. 6770625 August 2004 Soltero et al. 6867183 March 2005 Soltero et al. 6869930 March 2005 Havelund et al. 6902744 June 2005 Kolterman et al. 7030082 April 2006 Soltero et al. 7030083 April 2006 Schreiner et al. 2001/0041786 November 2001 Brader et al. 2002/0045731 April 2002 Schaffer et al. 2003/0027748 February 2003 Ekwuribe et al. 2003/0035775 February 2003 Klibanov 2003/0083232 May 2003 Soltero et al. 2003/0104981 June 2003 Mandic 2003/0134294 July 2003 Sandford et al. 2003/0166508 September 2003 Zhang 2004/0038867 February 2004 Still et al. 2004/0097410 May 2004 Zheng et al. 2004/0198949 October 2004 Ekwuribe et al. 2004/0254119 December 2004 West et al. 2005/0276843 December 2005 Quay et al. 2006/0019874 January 2006 Radhakrishnan et al. 2006/0183668 August 2006 Jonassen et al. 2008/0076705 March 2008 Kodra et al. 2010/0009898 January 2010 Nielsen et al. 2011/0105720 May 2011 Madsen et al. 2014/0073564 March 2014 Madsen et al. 1187119 July 1998 1314818 September 2001 1317958 October 2001 1390854 January 2003 214826 March 1987 265213 April 1988 376156 July 1990 511600 November 1992 544466 June 1993 712861 May 1996 712862 May 1996 925792 June 1999 1002547 May 2000 1121144 June 2002 894095 May 2003 894095 April 1962 1492997 November 1977 57-067548 April 1982 H01500116 January 1989 1-254699 October 1989 9-502867 March 1997 10-509176 September 1998 11-502110 February 1999 2000-501419 February 2000 2000-504732 April 2000 2001-521004 November 2001 2001-521006 November 2001 2001-521904 November 2001 2002-308899 October 2002 2002-543092 December 2002 WO 90/01038 February 1990 WO 91/12817 September 1991 WO 92/00321 January 1992 WO 92/01476 February 1992 WO 92/12999 August 1992 WO 94/08599 April 1994 WO 95/07931 March 1995 WO 95/13795 May 1995 WO 95/24183 September 1995 WO 96/15803 May 1996 WO 96/29344 September 1996 WO 96/37215 November 1996 WO 97/31022 August 1997 WO 98/01473 January 1998 WO 98/02460 January 1998 WO 99/21888 May 1999 WO 99/24071 May 1999 WO 99/65941 December 1999 WO 00/00176 January 2000 WO 00/10541 March 2000 WO 00/23098 April 2000 WO 00/42993 July 2000 WO 00/43034 July 2000 WO 00/61178 October 2000 WO 00/78302 December 2000 WO 02/094200 November 2002 WO 02/098232 December 2002 WO 02/098446 December 2002 WO 03/013573 February 2003 WO 03/022208 March 2003 WO 03/022996 March 2003 WO 03/047493 June 2003 WO 03/048195 June 2003 WO 03/053339 July 2003 WO 03/094951 November 2003 WO 03/094956 November 2003 WO 2004/105790 December 2004 WO 2005/005477 January 2005 WO 2005/012346 February 2005 WO 2005/012347 February 2005 WO 2005/016312 February 2005 WO 2005/047508 May 2005 WO 2005/049061 June 2005 WO 2005/055976 June 2005 WO 2005/058961 June 2005 WO 2005/092301 October 2005 WO 2006/023943 March 2006 WO 2006/079641 August 2006 WO 2006/082204 August 2006 WO 2006/082205 August 2006 WO 2006/097521 September 2006 WO 2007/006320 January 2007 WO 2007/041481 April 2007 WO 2007/047948 April 2007 WO 2007/074133 July 2007 WO 2007/081824 July 2007 WO 2007/096332 August 2007 WO 2007/096431 August 2007 WO 2007/104737 September 2007 WO 2007/128815 November 2007 WO 2007/128817 November 2007 WO 2008/015099 February 2008 WO 2008/034881 March 2008 WO 2008/132229 November 2008 WO 2008/145730 December 2008 WO 2009/010428 January 2009 WO 2009/022005 February 2009 WO 2009/022006 February 2009 2009/115469 September 2009 |
| Other References: | Glucagon for Injection, Marked-up Physician Package Insert, Eli Lilly and Company, Sep. 8, 1998. cited by examiner EXUBERA (insulin human [rDNA origin]) Inhalation Powder, US Package Insert, Jan. 27, 2006. cited by examiner Lai et al. “Solid-State Chemical Stability of Proteins and Peptides” Journal of Pharmaceutical Sciences, vol. 88, No. 5, May 1999, pp. 489-500. cited by examiner Farag Badway et al. “Microenvironmental pH Modulation in Solid Dosage Forms,” Journal of Pharmaceutical Sciences, vol. 96, No. 5, May 2007, pp. 948-959, published online Apr. 23, 2007. cited by examiner Kane et al., Physics ed.3, pp. 365 and 6-77. cited by applicant Lewis, Hawley's Condensed Chemical Dictionary, 1993, vol. 12, p. 1101. cited by applicant Bekerman et al., 2004, “Cyclosporin Nanoparticulate Lipospheres for Oral Administration,” Journal of Pharmaceutical Sciences 93(5):1264-1270. cited by applicant Bennett et al., 2003, “Insulin Inhibition of the Proteasome is Dependent on Degradation of Insulin by Insulin-Degrading Enzyme,” Journal of Endocrinology 177:399-405. cited by applicant Bhatnagar et al., 2006, “Molecular Variants and Derivatives of Insulin for Improved Glycemic Control in Diabetes,” Progress in Biophysics and Molecular Biology 91(3):199-228. cited by applicant Chin et al., 1994, “Communication to the Editor: On Protein Solubility in Organic Solvents,” Biotechnology and Bioengineering 44:140-145. cited by applicant Chu et al., 1992, “The A14 Position of Insulin Tolesrates Considerable Structural Alterations With Modest Effects on the Biological Behavior of the Hormone,” Journal of Protein Chemistry 11(5):571-577. cited by applicant Hartmann et al., 1992, “Comparison of Subcutaneously Administered Soluble Insulin and Des-(B26-B30)-Insulin-B25-Amide in Rabbit, Pig and Healthy Man,” Diabetes Research and Clinical Practice 16(3):175-181. cited by applicant Hashimoto et al., 1989, “Synthesis of Palmitoyl Derivatives of Insulin and Their Biological Activities” Pharmaceutical Research 6(2):171-176. cited by applicant Havelund et al., 2004, “The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin” Pharmaceutical Research 21(8):1498-1504. cited by applicant Hinds et al., 2000, “Synthesis and Characterization of Poly(Ethylene Glycol)-Insulin Conjugates,” Bioconjugate Chemistry 11(2):195-201. cited by applicant Hinds et al., 2002, “Effects of Peg Conjugation on Insulin Properties,” Advanced Drug Delivery Reviews 54(4):505-530. cited by applicant Iwamoto, 2000, “New Insulin Formulation,” Annual Review Endocrine Metabolism pp. 46-53. cited by applicant Jonassen et al., 2006, “Synthesis of Palmitoyl Derivatives of Insulin and Their Biological Activities,” Pharmaceutical Research 23(1):49-55. cited by applicant Kochendoerfer et al., 2003, “Design and Chemical Synthesis of a Homogenous Polymer-Modified Erythropoiesis Protein,” Science 299:884-887. cited by applicant Kurtz et al., 1983, “Circulating IgG Antibody to Protamine in Patients Treated with Protamine-Insulins,” Diabetologia 25(2):322-324. cited by applicant Markussen et al., 1987, “Soluble, Prolonged-Acting Insulin Derivatives. I. Degree of Protraction, Crystallizability of Insulins Substituted in the . . . ” Protein Engineering 1(3):205-213. cited by applicant Markussen et al., 1988, “Soluble, Prolonged-Acting Insulin Derivatives. III. Degree of Protraction, Crystallizability and Chemical Stability of Insulins Substituted in Positions A21, B13, B23, B27 and B30,” Protein Engineering 2(2):157-166. cited by applicant Muranishi et al., 1992, “Trials of Lipid Modification of Peptide Hormones for Intestinal Delivery,” Journal of Controlled Release 19:179-188. cited by applicant Samuel et al., 1978, “Studies on the Immunogenicity of Protamines in Humans Andexperimental Animals by Means of a Micro-Complement Fixation Test,” Clinical Experminemtal Immunology 33:252-260. cited by applicant Schilling et al., 1991, “Degradation of Insulin by Trypsin and Alpha Chymotrypsin,” Pharmaceutical Research 8(6):721-727. cited by applicant Schlichtkrull et al., 1956, “Insulin Crystals,” Acta Chemica Scandinavica 10(9):1455-1458. cited by applicant Seabright et al., 1996, “The Characterization of Endosomal Insulin Degradation Intermediates and Their Sequence of Production,” Biochemical Journal 320(3):947-956. cited by applicant Stentz et al., 1989, “Identification of Insulin Intermediates and Sites of Cleavage of Native Insulin by Insulin Protease From Human Fibroblasts,” Journal of Biological Chemistry 264(34):20275-20285. cited by applicant Toorisaka et al., 2004, “Emulsion-Based Drug Delivery Systems,” Membrane 29(2):98-104 Abstract. cited by applicant Uchio et al., 1999, “Site-Specific Insulin Conjugates With Enhanced Stability and Extended Action Profile,” Advanced Drug Delivery Reviews 35:289-306. cited by applicant Whittingham et al., 2004, “Crystallographic and Solution . . . ” Biochemistry 43:5987-5995. cited by applicant JP 10-509176 Machine Translation Sep. 8, 1998. cited by applicant JP 11-502110 Machine Translation Feb. 23, 1999. cited by applicant JP 1-254699 English Abstract Oct. 11, 1989. cited by applicant JP 2000-501419 Machine Translation Feb. 8, 2000. cited by applicant JP 2000-504732 Machine Translation Apr. 18, 2000. cited by applicant JP 2001-521004 Machine Translation Nov. 6, 2001. cited by applicant JP 2001-521006 Machine Translation Nov. 6, 2001. cited by applicant JP 2001-521904 Machine Translation Nov. 13, 2001. cited by applicant JP 2002-308899 Machine Translation Oct. 23, 2002. cited by applicant JP 2002-543092 Machine Translation Dec. 17, 2002. cited by applicant JP 57-067548 English Abstract Apr. 24, 1982. cited by applicant JP 9-502867 Machine Translation Mar. 25, 1997. cited by applicant Non-Final Office Action mailed Jul. 12, 2010 in U.S. Appl. No. 12/560,833, filed Sep. 16, 2009 by Jonassen et al. cited by applicant Notice of Abandonment mailed Jul. 23, 2010 in U.S. Appl. No. 11/814,374, filed Jan. 29, 2008 by Garibay et al. cited by applicant Non-Final Office Action mailed Nov. 17, 2009 in U.S. Appl. No. 11/814,374, filed Jan. 29, 2008 by Garibay et al. cited by applicant Non-Final Office Action mailed Apr. 17, 2009 in U.S. Appl. No. 11/814,374, filed Jan. 29, 2008 by Garibay et al. cited by applicant Non-Final Office Action mailed Sep. 24, 2010 in U.S. Appl. No. 11/814,019, filed Oct. 4, 2007 by Kodra et al. cited by applicant Advisory Action mailed Jul. 23, 2010 in U.S. Appl. No. 11/814,019, filed Oct. 4, 2007 by Kodra et al. cited by applicant Final Office Action mailed Feb. 1, 2010 in U.S. Appl. No. 11/814,019, filed Oct. 4, 2007 by Kodra et al. cited by applicant Non-Final Office Action mailed Jun. 18, 2009 in U.S. Appl. No. 11/814,019, filed Oct. 4, 2007 by Kodra et al. cited by applicant Notice of Allowance mailed Sep. 8, 2009 in U.S. Appl. No. 11/343,005, filed Jan. 30, 2006 by Jonassen et al. cited by applicant Advisory Action mailed Mar. 20, 2009 in U.S. Appl. No. 11/343,005, filed Jan. 30, 2006 by Jonassen et al. cited by applicant Final Office Action mailed Dec. 24, 2008 in U.S. Appl. No. 11/343,005, filed Jan. 30, 2006 by Jonassen et al. cited by applicant Non-Final Office Action mailed Jul. 11, 2008 in U.S. Appl. No. 11/343,005, filed Jan. 30, 2006 by Jonassen et al. cited by applicant Notice of Allowance mailed Feb. 6, 2007 in U.S. Appl. No. 10/620,651, filed Jul. 16, 2003 by Markussen et al. cited by applicant Non-Final Office Action mailed Jun. 27, 2006 in U.S. Appl. No. 10/620,651, filed Jul. 16, 2003 by Markussen et al. cited by applicant Notice of Allowance mailed Apr. 9, 2003 in U.S. Appl. No. 09/861,687, filed May 21, 2001 by Markussen et al. cited by applicant Non-Final Office Action mailed Sep. 27, 2002 in U.S. Appl. No. 09/861,687, filed May 21, 2001 by Markussen et al. cited by applicant Notice of Allowance mailed Feb. 22, 2001 in U.S. Appl. No. 08/932,082, filed Sep. 17, 1997 by Markussen et al. cited by applicant Final Office Action mailed Oct. 20, 2000 in U.S. Appl. No. 08/932,082, filed Sep. 17, 1997 by Markussen et al. cited by applicant Non-Final Office Action mailed May 23, 2000 in U.S. Appl. No. 08/932,082, filed Sep. 17, 1997 by Markussen et al. cited by applicant Final Office Action mailed Jun. 17, 1999 in U.S. Appl. No. 08/932,082, filed Sep. 17, 1997 by Markussen et al. cited by applicant Non-Final Office Action mailed Sep. 23, 2008 in U.S. Appl. No. 08/932,082, filed Sep. 17, 1997 by Markussen et al. cited by applicant Notice of Abandonment mailed Mar. 12, 1998 in U.S. Appl. No. 08/448,210, filed May 23, 1995 by Markussen et al. cited by applicant Notice of Allowance mailed May 27, 1997 in U.S. Appl. No. 08/448,210, filed May 23, 1995 by Markussen et al. cited by applicant Non-Final Office Action mailed May 30, 1996 in U.S. Appl. No. 08/448,210, filed May 23, 1995 by Markussen et al. cited by applicant Aminlari, M. et al., Protein Dispersibility of Spray-Dried Whole Soybean Milk Base: Effect of Processing Variables, Journal of Food Science, vol. 42 (4), pp. 985-988 (1977). cited by applicant Foster, T., et al., Powder Characteristics of Proteins Spray-Dried From Different Spray-Dryers, Drug Development and Industrial Pharmacy, vol. 21 (15), 1705-23 (1995). cited by applicant Abstract of Chinese Patent 1390854 Granted Sep. 8, 2004. cited by applicant |
| Primary Examiner: | Bradley, Christina |
| Attorney, Agent or Firm: | Hu, Jianjie |
| رقم الانضمام: | edspgr.09387176 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |